Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title. Swiss pharmaceutical giant Novartis AG ...

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several ...

A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in second-quarter sales and earnings.

We recently published 8 Stocks That Jim Cramer Recently Talked About. Novartis AG (NYSE:NVS) is one of the stocks Jim Cramer ...

Novartis made one of the biggest investments in Cannes among pharma companies, sending approximately 20 people from the ...

Novartis manufacturing sites work diligently to produce CAR-T cell therapy. The company is globally expanding its manufacturing sites to give more patients access to CAR-T.

Novartis AG NOVN -0.38% launched a lottery-style program to provide doses of its pricey gene therapy free of charge, drawing criticism from patient groups that called it an inappropriate way to ...